Alana Asciutti Victorino, Fernando Veiga Angélico Júnior, Paula Ribeiro Lopes Almeida, Priscila Bogar, Osmar Clayton Person
{"title":"文拉法辛预防前庭偏头痛的有效性和安全性","authors":"Alana Asciutti Victorino, Fernando Veiga Angélico Júnior, Paula Ribeiro Lopes Almeida, Priscila Bogar, Osmar Clayton Person","doi":"10.56242/globalhealth;2021;1;3;57-61","DOIUrl":null,"url":null,"abstract":"OBJECTIVE: To evaluate the efficacy and safety of Venlafaxine for the control of vestibular migraine (VM). METHODS: This is a systematic review of randomized clinical trials. The following databases were searched: PUBMED (1966-2021), EMBASE (1974-2021) and CENTRAL (Cochrane Library-2021). There was no geographic and period limitation in the survey. Data extraction and study quality assessment were carried out by two independent researchers. RESULTS: The search strategy identified 47 studies, of which 2 were included in this review, as they met the inclusion and exclusion criteria. Both evaluated the efficacy of venlafaxine in vestibular migraine, comparing the results with other drugs. The first study (2017) compared the effect of venlafaxine with flunarizine and valproic acid, while the second study (2015) compared the efficacy of venlafaxine with propranolol. Both showed improvement of vestibular symptoms in all groups evaluated, but only the groups submitted to treatment with venlafaxine showed a significant change in the emotional DHI (Dizziness Handicap Inventory) score and improvement in depressive symptoms. CONCLUSIONS: Although venlafaxine appears to have promising results, there is currently a scarcity of studies that allow currently to assess the efficacy and safety of the drug for the treatment of vestibular migraine. The evidence is quite limited, the number of studies and patients evaluated reduced, and it is recommended to conduct new quality randomized clinical trials to elucidate the issue.","PeriodicalId":285800,"journal":{"name":"Brazilian Journal of Global Health","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Eficácia e segurança da Venlafaxina para prevenção de migrânea vestibular\",\"authors\":\"Alana Asciutti Victorino, Fernando Veiga Angélico Júnior, Paula Ribeiro Lopes Almeida, Priscila Bogar, Osmar Clayton Person\",\"doi\":\"10.56242/globalhealth;2021;1;3;57-61\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE: To evaluate the efficacy and safety of Venlafaxine for the control of vestibular migraine (VM). METHODS: This is a systematic review of randomized clinical trials. The following databases were searched: PUBMED (1966-2021), EMBASE (1974-2021) and CENTRAL (Cochrane Library-2021). There was no geographic and period limitation in the survey. Data extraction and study quality assessment were carried out by two independent researchers. RESULTS: The search strategy identified 47 studies, of which 2 were included in this review, as they met the inclusion and exclusion criteria. Both evaluated the efficacy of venlafaxine in vestibular migraine, comparing the results with other drugs. The first study (2017) compared the effect of venlafaxine with flunarizine and valproic acid, while the second study (2015) compared the efficacy of venlafaxine with propranolol. Both showed improvement of vestibular symptoms in all groups evaluated, but only the groups submitted to treatment with venlafaxine showed a significant change in the emotional DHI (Dizziness Handicap Inventory) score and improvement in depressive symptoms. CONCLUSIONS: Although venlafaxine appears to have promising results, there is currently a scarcity of studies that allow currently to assess the efficacy and safety of the drug for the treatment of vestibular migraine. The evidence is quite limited, the number of studies and patients evaluated reduced, and it is recommended to conduct new quality randomized clinical trials to elucidate the issue.\",\"PeriodicalId\":285800,\"journal\":{\"name\":\"Brazilian Journal of Global Health\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brazilian Journal of Global Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.56242/globalhealth;2021;1;3;57-61\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brazilian Journal of Global Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56242/globalhealth;2021;1;3;57-61","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Eficácia e segurança da Venlafaxina para prevenção de migrânea vestibular
OBJECTIVE: To evaluate the efficacy and safety of Venlafaxine for the control of vestibular migraine (VM). METHODS: This is a systematic review of randomized clinical trials. The following databases were searched: PUBMED (1966-2021), EMBASE (1974-2021) and CENTRAL (Cochrane Library-2021). There was no geographic and period limitation in the survey. Data extraction and study quality assessment were carried out by two independent researchers. RESULTS: The search strategy identified 47 studies, of which 2 were included in this review, as they met the inclusion and exclusion criteria. Both evaluated the efficacy of venlafaxine in vestibular migraine, comparing the results with other drugs. The first study (2017) compared the effect of venlafaxine with flunarizine and valproic acid, while the second study (2015) compared the efficacy of venlafaxine with propranolol. Both showed improvement of vestibular symptoms in all groups evaluated, but only the groups submitted to treatment with venlafaxine showed a significant change in the emotional DHI (Dizziness Handicap Inventory) score and improvement in depressive symptoms. CONCLUSIONS: Although venlafaxine appears to have promising results, there is currently a scarcity of studies that allow currently to assess the efficacy and safety of the drug for the treatment of vestibular migraine. The evidence is quite limited, the number of studies and patients evaluated reduced, and it is recommended to conduct new quality randomized clinical trials to elucidate the issue.